Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ophthalmologic Safety of Pramipexole in Parkinson's Disease
NCT02233023Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 1998
- Primary completion
- Jun 2000
- Modality
- Small Molecules
01
Overview
Phase 4, single-blind trial of pramipexole in Parkinson's disease (PD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of drug related signs of retinal degeneration at 8 months. Started Jun 1998; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02233023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02233023.